Heparinum Wzf (Heparin Sodium)

Heparinum Wzf is indicated for several anticoagulation purposes in hospital and surgical environments.

• Prevention and treatment of deep vein thrombosis (DVT) in at‑risk patients.
• Prevention and treatment of pulmonary embolism (PE) following clot formation.
• Anticoagulation during cardiac surgery, including cardiopulmonary bypass procedures.
• Anticoagulation for patients undergoing hemodialysis to maintain circuit patency.
• Prophylaxis of clot formation in patients with acute coronary syndromes undergoing interventional procedures.

Adverse reactions to Heparinum Wzf vary in frequency and severity, ranging from mild to potentially life‑threatening.

Common

• Minor bleeding at the injection site or bruising.
• Small drops in platelet count (thrombocytopenia) without clinical symptoms.
• Elevated liver enzymes detected in routine laboratory tests.
• Nausea or mild headache.

Serious

• Major hemorrhage, including internal bleeding.
• Heparin‑induced thrombocytopenia (HIT) with paradoxical clot formation.
• Severe allergic reactions such as anaphylaxis.

Before initiating Heparinum Wzf therapy, clinicians should evaluate several safety considerations to minimize risk.

• Assess patient history for bleeding disorders or recent major surgery.
• Monitor activated partial thromboplastin time (aPTT) or anti‑Xa levels during treatment.
• Use caution in patients with renal or hepatic impairment.
• Avoid use in individuals with known hypersensitivity to heparin or pork‑derived products.
• Evaluate platelet counts regularly to detect heparin‑induced thrombocytopenia.
• Consider dose adjustment in elderly or low‑body‑weight patients.
• Discontinue therapy promptly if uncontrolled bleeding occurs.

Heparinum Wzf may interact with other medications that affect hemostasis or drug metabolism, requiring careful management.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) unless specifically directed.
• Combined therapy with antiplatelet agents such as aspirin, clopidogrel, or ticagrelor without monitoring.
• Administration with fibrinolytic agents (e.g., alteplase) due to heightened bleeding risk.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase bleeding tendency.
• Certain antibiotics (e.g., vancomycin) that can potentiate anticoagulant effects.
• Herbal supplements like ginkgo biloba, garlic, or high‑dose vitamin E.